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Histone methylation/demethylation plays an important modulatory role in chromatin
restructuring, RNA transcription and is essential for controlling a plethora of
biological processes. Due to many human diseases have been related to
histone methylation/demethylation, several compounds such as 3-deazaneplanocin
A (DZNep) or 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-
4-yl)amino)propanoic acid; N-[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-
yl)-4-pyrimidinyl]-β-Alanine (GSK-J1), have been designed to inhibit histone methylase
or suppress histone demethylase, respectively. In the present study, we investigated the
effects on the sleep-wake cycle and sleep-related neurochemical levels after systemic
injections of DZNep or GSK-J1 given during the light or dark phase in rats. DZNep
dose-dependently (0.1, 1.0, or 10 mg/kg, i.p.) prolonged wakefulness (W) duration
while decreased slow wave sleep (SWS) and rapid eye movement sleep (REMS)
time spent during the lights-on period with no changes observed in dark phase. In
opposite direction, GSK-J1 (0.1, 1.0, or 10 mg/kg, i.p.) injected at the beginning of
the lights-on period induced no statistical changes in W, SWS, or REMS whereas
if administered at darkness, we found a diminution in W and an enhancement in
SWS and REMS. Finally, brain microdialysis experiments in freely moving animals were
used to evaluate the effects of DZNep or GSK-J1 treatments on contents of sleep-
related neurochemicals. The results showed that DZNep boosted extracellular levels
of dopamine, norepinephrine, epinephrine, serotonin, adenosine, and acetylcholine if
injected at the beginning of the lights-on period whereas GSK-J1 exerted similar
outcomes but when administered at darkness. In summary, DZNep and GSK-J1
may control the sleep-wake cycle and sleep-related neurochemicals through histone
methylation/demethylation activity.
Keywords: adenosine, dopamine, histone demethylation, serotonin, sleep, wakefulness
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INTRODUCTION
DNA methylation and modifications of histones are part of
molecular mechanisms that control gene expression promoting
the stabilization of the genome as well (Almeida et al., 2017;
Bauer and Martin, 2017; Kim and Kaang, 2017; Pasculli et al.,
2018). In the recent years, multiple studies have demonstrated the
relationship between histone methylation/demethylation activity
and various human pathologies, such as cancer (Zaidi et al.,
2017; Zam and Khadour, 2017). Understanding the molecular
mechanism by which histone methylation/demethylation
is translated into molecular modulators is essential to
developing medicinal approaches for disease genetics and
genome-related medicine.
This research area is complex, but there is an increasing
appreciation of the role of histones in health and disease.
Current experimental pharmacological approaches for treating
histone-related disorders are based on designed drugs aimed
to manage genetic-related health disturbances (Li et al., 2016;
Boehm and Ott, 2017; McCabe et al., 2017; Kaniskan et al.,
2018; Khan and Haqqi, 2018; Thomas and D’Mello, 2018).
Converging studies have suggested that compounds such as
3-deazaneplanocin A (DZNep), inhibits histone trimethylation




-4-pyrimidinyl]-β-Alanine (GSK-J1), the histone demethylase
activity is suppressed (Dagdemir et al., 2016; Kuntz et al., 2016;
Kaniskan et al., 2018; Zheng et al., 2018).
The histone methylation/demethylation activity is a promising
target for exploring therapeutical options to treating multiple
disorders. More recently, it has been demonstrated the role
of histones in neurodegenerative diseases, aging, learning and
memory (Jês´ko et al., 2017; Kaluski et al., 2017; Zhao et al., 2018).
Thus, the rationale use of histone methylation/demethylation
inhibitors represents potential utility of DZNep or GSK-J1 in
the comprehension of the role of histones in neurobiological
processes, such as the sleep-wake cycle. In this report, we
investigated the behavioral and neurochemical consequences that
result from systemic injections of DZNep or GSK-J1, specifically
in the sleep-wake cycle and extracellular levels of monoamines,
adenosine and acetylcholine in rats.
MATERIALS AND METHODS
Experiment 1: Effects on Sleep After
Injections of DZNep or GSK-J1 During
the Lights-On or the Lights-Off Period
Ethics Statement
The whole experimental procedures were approved by the
Research and Ethics Committee of our Institution fulfilling
the Mexican Standards Related to Use and Management of
Laboratory Animals (DOF. NOM-062-Z00-1999), the U.K.
Animals Scientific Procedures (Act, 1986 and associated
guidelines, EU Directive 2010/63/EU for animal experiments),
National Institute of Health (NIH Publication No. 80-23, revised
1996 and Guide for the Care and Use of Laboratory Animals,
8th Edn, 2011), and ARRIVE standards of Animal Welfare.
For ethical reasons, efforts to minimize animal suffering were
considered during the whole experiment and a reduced number
of animals were included in the current report.
Animals
Male Wistar rats (n = 20; 250–300 g) were singly housed in
polycarbonate cages (48.26 cm × 26.67 cm × 20.32 cm; Harlan
Laboratories, Mexico) under humidity (60 ± 10%), ambient
temperature (21 ± 1◦C) and light–dark cycle 12:12 (lights-on:
07:00–19:00 h) controlled. All rats had free access to Purina Rat
Chow (Purina, Mexico) as well as tap water.
Chemical
Chemical compounds studied in this article DZNep (PubChem
CID: CID: 73087); GSK-J1 (PubChem CID: 56963315);
polyethylene glycol (PubChem CID: 174). More information
is available at https://pubchem.ncbi.nlm.nih.gov/. DZNep
and GSK-J1 were purchased from Sigma (St. Louis, MO,
United States) and dissolved in a vehicle (VEH) solution
composed of polyethylene glycol/saline (5:95 v/v) as previously
reported (Miranda et al., 2009; Johansson et al., 2016). Additional
reagents, chemicals, and materials were purchased from Sigma-
Aldrich (St. Louis, MO, United States) or Bioanalytical Systems
(West Lafayette, IN, United States).
Sleep-Recording Surgeries
Anesthesia (acepromazine [0.75 mg/kg], xylazine [2.5 mg/kg],
and ketamine [22 mg/kg]) was given (i.p.) to rats to place them
in a stereotaxic frame (David Kopf Instruments, Tujunga, CA,
United States) for sleep-recording electrodes surgery. Briefly, two
stainless-steel screw electrodes were placed 2 mm on either side
of the sagittal sinus and 3 mm anterior to Bregma (frontal cortex).
Other two screws were located 3 mm on either side of the sagittal
sinus and 6 mm behind Bregma (occipital cortex). The whole
electrodes recorded the electroencephalogram (EEG) activity by
the bipolar (differential) EEG recorded from the two contralateral
screw electrodes (frontal-occipital). The electromyogram (EMG)
activity was obtained by the implantation of two wire electrodes
into the dorsal neck muscles. Finishing the EEG/EMG electrode
implantation, the wires were inserted into a six-pin plastic plug
(Plastics One, Roanoke, VA, United States) and attached onto
the skull by dental cement. Upon completion of the EEG/EMG
electrodes surgeries, animals were placed into individual cages
with food and water ad libitum. In addition, rats were connected
to a 6-channel slip-ring commutator through a 50 cm cable
(Plastics One, Roanoke, VA, United States), which allowed free
moving of animal around the cage. The EEG/EMG electrodes
surgical procedure as well as habituation conditions were carried
out as reported previously (Murillo-Rodríguez et al., 2017).
Pharmacological Administrations
Right after the surgeries, animals spent seven continuous days
for recovery from EEG/EMG electrodes surgery as well as for
habituation to the experimental conditions. Once completed
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this period, animals were placed randomly into one of the
experimental blocks (either lights-on or lights-off period):
Control ([CTL] VEH; n = 5), DZNep (0.1, 1.0, or 10 mg/kg,
i.p.; each dose, n = 5) or GSK-J1 (0.1, 1.0, or 10 mg/kg, i.p.;
each dose, n = 5). Doses of compounds were chosen arbitrarily
since no direct evidence was available regarding their effects
on freely moving rats. Moreover, the route of administration
of compounds was selected to obtain a preliminary approach
for an understanding of the putative phenomena. To avoid
circadian influences in the pharmacological treatments of
the histone methylation/demethylation activity on sleep, the
administrations were done 1 h after either the start of
the lights-on or the lights-off period. Thus, animals were
disconnected from the sleep-recording system and experimental
trials were administered. Once experimental challenges were
applied, rats were reattached to the sleep-recording system and
sleep data were collected across the next 4 h. Lastly, due to
the reduced number of animals used for ethical reasons, the
experiment was under a single-blind Latin Square Experimental
Design. Since each subject serves as its own control, the testing
paradigm has the advantage of decreasing variability among
experimental conditions.
Analysis of Sleep Recordings
The sleep data were collected during the following 4 h
post-injections sampled in periods of 12 s (epochs). Next,
differentiation of wakefulness (W), slow wave sleep (SWS),
or rapid eye movement sleep (REMS) was based on the
characterization of each phase by the aid of the sleep-scoring
program (ICELUS) as previously reported (Murillo-Rodríguez
et al., 2017). One observer blind to the experiments analyzed
sleep recordings.
Power Spectra Analysis
Fast Fourier transformation analysis for alpha (across W
[α: 12–16 Hz]), delta (for SWS [1: 0.3–4.0 Hz]), and theta
(during REMS [2: 6.0–12.0 Hz]) was collected during either
lights-on or lights-off after experimental trials. This data provided
information about quality rather than quantity of the sleep
stages under the influence of treatments. Data were analyzed
as previously reported (Murillo-Rodríguez et al., 2017). One
observer blind to the experiments analyzed power spectra.
Statistical Analysis
The data for the experimental results were presented as
mean ± SEM. The data were examined by ANOVA test followed
by Scheffé’s post hoc test using the StatView software (version
5.0.0, SAS Institute, United States). Statistical differences among
groups were determined if P < 0.05.
Experiment 2: Effects on the
Extracellular Levels of Monoamines After
Administrations of DZNep or GSK-J1
Animals
A new set of male Wistar rats (n= 20; 250–300 g) were maintained
as described in Experiment 1.
Chemicals
As described in Experiment 1.
Microdialysis Surgeries
Previous results have shown the role of the nucleus accumbens
(AcbC) in the sleep-wake cycle modulation (Qiu et al., 2012).
Moreover, studies from our group have demonstrated reliable
measurements of sleep-related neurochemicals such as dopamine
(DA), norepinephrine (NE), epinephrine (EP), serotonin (5-HT),
of samples collected from AcbC (Mijangos-Moreno et al., 2014,
2016; Murillo-Rodríguez et al., 2017). Thus, we determined
whether DZNep or GSK-J1 might exert changes in the levels
of these neurochemicals as characterized from microdialysis
samples collected from AcbC. To achieve this goal, animals were
anesthetized and mounted into the stereotaxic frame (David Kopf
Instruments, Tujunga, CA, United States) for implantation of
a microdialysis guide-cannula (IC guide; BioAnalytical Systems
[BAS], West Lafayette, IN, United States) aimed unilaterally
into the AcbC (coordinates: A = +1.2, L = +2.0, and
H = −7.0 mm, with reference to Bregma [Paxinos and Watson,
2005]). Right after the surgery, rats were placed individually
into the microdialysis bowl (Raturn Microdialysis Stand-Alone
System, MD-1404, BAS, West Lafayette, IN, United States)
for post-surgery recovery (seven continuous days) as well
as habituation for the experimental conditions. All surgical
procedures of microdialysis surgery were accomplished as
previously reported (Murillo-Rodríguez et al., 2017).
Pharmacological Administrations
As described in Experiment 1.
Microdialysis Sampling Procedures
Once reaching the recovery and habituation time, animals
were removed from microdialysis bowls and the stylet from
guide-cannula was withdrawn. Next, the microdialysis probe
(1 mm of length; polyacrylonitrile, MWCO = 30,000 Da; 340 µm
OD; BAS, West Lafayette, IN, United States) was inserted at
07:00 h. Artificial cerebrospinal fluid (aCSF [composition: NaCl
147 mM, KCl 3 mM, CaCl 1.2 mM, MgCl 1.0 mM, pH 7.2]) was
perfused through a miniature tube (0.65 mm OD × 0.12 mm
ID; BAS, West Lafayette, IN, United States) attached to a
2.5 mL syringe (BAS, West Lafayette, IN, United States) with
a pump (flow rate: 0.25 µL/min; BAS Bee, West Lafayette, IN,
United States). As standardized procedure, before the beginning
of the experiments, in all rats, the microdialysis membrane
was stabilized during 24 h and samples from that period were
excluded for the final analysis as suggested from previous reports
(Mijangos-Moreno et al., 2014, 2016; Murillo-Rodríguez et al.,
2017). Right after the period of stabilization of membrane
was covered, experimental trials were given and animals were
reattached to the microdialysis system. The dialysates were
collected every 20 min at the beginning of each hour during
the following 4 h. Later, all samples were stored (−80◦C)
for further analysis. The microdialysis sampling procedure was
developed as previous reports (Mijangos-Moreno et al., 2014,
2016; Murillo-Rodríguez et al., 2017).
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Neurochemical Analysis of Monoamines
Dialysates collected from sampling were filtered (Millipore
0.22 µm; Merck Millipore, Darmstadt, Germany) and injected
into high performance liquid chromatography (HPLC; Modular
Prominence, Shimadzu, Kyoto, Japan). For monoamines
detection, the HPLC used mobile phase (monosodium
phosphate) ([7 mM, pH 3.0], plus methanol [3.5%]) which was
perfused at flow rate of 80 µL/min (pump LC-20AT, Shimadzu,
Kyoto, Japan). Separation of molecules was achieved by using a
microbore column (octadecyl silica [3 µm, 100 mm × 1 mm],
BAS, West Lafayette, IN, United States) with temperature
controlled (22◦C; oven CTO-20A, Shimadzu, Kyoto, Japan).
The detection of monoamines was obtained by using an
electrochemical detector (LC-4C; BAS, West Lafayette, IN,
United States). The chromatographic data were obtained
and stored on a personal computer (via computer controller
CBM-20A, Shimadzu, Kyoto, Japan). The concentrations of
monoamines in the samples were obtained by comparing
external known standards for the neurochemicals studied (DA,
NE, EP, and 5-HT) injected into HPLC. The whole HPLC
procedures were developed as described previously (Murillo-
Rodríguez et al., 2017). One observer blind to the code of
experimental samples analyzed contents of monoamines.
Statistical Analysis
The total values for monoamines contents consisted in samples
summed from continuous 4 h. All data from microdialysis
experiments were represented as mean ± SEM. Statistical
differences among the experimental groups were determined
by one-way ANOVA followed by Scheffé’s post hoc test for
multiple comparisons. All statistical analyses were performed
using the StatView software (version 5.0.0, SAS Institute,
United States) and statistical differences among groups were
determined if P < 0.05.
Experiment 3: Effects on the
Extracellular Contents of Adenosine
After Treatments of DZNep or GSK-J1
Animals
As described in Experiment 2.
Chemicals
As described in Experiment 2.
Microdialysis Surgeries
As described in Experiment 2.
Administration of Drugs
As described in Experiment 1.
Microdialysis Sampling Method
As described in Experiment 2.
Neurochemical Analysis of Adenosine
Similar chromatographic conditions as described for detection
of monoamines were used for adenosine (AD) analysis.
Methodological differences consisted in using an UV detector
(SPD-20A Prominence, Shimadzu, Kyoto, Japan) setting the
wavelength at 254 nm (deuterium lamp) and mobile phase
(10 mM sodium dihydrogen phosphate [pH 4.5] and methanol
[9%]) which was perfused at a flow rate of 80 µL/min
using a pump (LC-20AT, Prominence HPLC, Shimadzu, Kyoto,
Japan). All chromatographic data for AD detection were
recorded in a personal computer, and peak heights of this
purine in dialysates were compared with external known
standards by using chromatograph report software (LC Solution,
Shimadzu, Kyoto, Japan). The whole procedure for detection
and measurement of AD using HPLC means was developed
according to previous reports (Mijangos-Moreno et al., 2014;
Murillo-Rodríguez et al., 2017). Contents of AD were analyzed
under a blind experimental design.
Statistical Analysis
As described in Experiment 2.
Experiment 4: Effects on the
Extracellular Contents of Acetylcholine
After Administrations of DZNep or
GSK-J1
Animals
A new set of male Wistar rats (n = 20; 250–300 g) were used as
described in Experiment 2.
Chemicals
As described in Experiment 1.
Microdialysis Surgeries
The importance of basal forebrain in the sleep-wake modulation
has been previously reported (Anaclet et al., 2015; Gold et al.,
2015; Xu et al., 2015). Moreover, it has been demonstrated that
acetylcholine (ACh) is measurable from the mentioned brain
area (Vanini et al., 2012; Zaghloul et al., 2017). Then, in this
part of the study, we placed the microdialysis probe into the
basal forebrain following stereotaxic coordinates (A = −0.35;
L = 2.0; and H = −7.5 mm, with reference to Bregma [Paxinos
and Watson, 2005]). All microdialysis surgery procedure was
developed as described in Experiment 2.
Pharmacological Administrations
As described in Experiment 2.
Microdialysis Sampling Procedures
As described in Experiment 2 with exception of aCSF (KCl
[2.4 nM], Na2SO4 [0.5 nM], NaCl [126.5 nM], CaCl2 [1.2 nM],
NaHCO3 [27.5 nM], KH2PO4 [0.5 nM], MgCl2 [0.8 nM],
dextrose [5.0 nM] at pH [6.8± 0.1]) which was perfused through
a miniature tubing (0.65 mm OD × 0.12 mm ID; BAS, West
Lafayette, IN, United States) attached to a 2.5 mL syringe (BAS,
West Lafayette, IN, United States) with a pump (flow rate:
2 µL/min; BAS Bee, West Lafayette, IN, United States).
Analysis of Contents of Acetylcholine Using the HPLC
As described in Experiment 2 with exception of conditions
for ACh detection. In detail: neostigmine bromide (100 nM)
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was added to the aCSF to facilitate detection of ACh contents.
Moreover, the use of acetylcholine-choline assay kit (MF-8910;
BAS, West Lafayette, IN, United States) was included for
detection of ACh. Next, for separation of molecule, samples
were injected into the HPLC at a flow rate of 1 mL/min, with
temperature of 28◦C (oven CTO-20A, Shimadzu, Kyoto, Japan),
on 10 cm analytical column (MF-6150, BAS, West Lafayette, IN,
United States) by using a mobile phase (Na2HPO4 [35 nM],
EDTA [0.1 nM], and ProClin 150 preservative (0.005%), BAS,
West Lafayette, IN, United States), and adjusted to pH 8.5 with
phosphoric acid. By electrochemical means (LC-4C; BAS, West
Lafayette, IN, United States) and maintaining the potential of
+0.5 V, ACh was detected in collected samples. The analytical
procedure to determinate ACh was developed as previous reports
(Grupe et al., 2013; Murillo-Rodríguez et al., 2018). Extracellular
levels of ACh were analyzed under a blind experimental design.
Recovery in vitro for Calibration of Microdialysis
Probes
In the whole microdialysis experiments, measuring monoamines,
AD or ACh, the microdialysis probes were used no more than
five continuous days since previous reports have shown that
the permanence of the cannula in the study area for more
than 5 days diminishes the membrane ability to transport fluid
through the microdialysis probe pores (Porkka-Heiskanen et al.,
2000; Murillo-Rodríguez et al., 2004). In addition, we developed
recovery test of microdialysis cannula by inserting the probes
into a test solution containing external known concentrations
of monoamines, AD or ACh under controlled perfusion of
respective mobile phase. Dialysates were collected in a triplicate
fashion under these experimental conditions. Each sample
collected from in vitro recovery study was analyzed and the peak
area ratio for monoamines, AD or ACh was calculated against
the known standards. For obtaining the recovery rate, data were
calculated by using the formulae: recovery rate (%) D (the peak
area ratio of the sample from microdialysis sample)/(the peak
area ratio of the sample in the test solution). The whole recovery
in vitro for calibration of microdialysis probes procedure was
carried out as previous reports (Porkka-Heiskanen et al., 2000;
Murillo-Rodríguez et al., 2004; Blanco-Centurión et al., 2006).
Histological Verification of Probe Location in
Microdialysis Experiments
After all microdialysis experiments, rats were sacrificed with
a lethal dose of pentobarbital for the standard procedure
for vascular perfusion (saline solution [0.9%] followed by
formaldehyde [4%]). Next, the brain was removed and post-fixed
overnight in formaldehyde (4%) followed by 10, 20, and 30%
sucrose/0.1 M PBS during 24 h (each concentration). At last, all
brains were cut in coronal sections (20 µm) using a Portable
Bench-top Cryostat (Leica CM1100, Wetzlar, Germany) and
collected in 1:5 serial order. One serial was used for probe
location and it was identified by plotting using rat brain atlas
(Paxinos and Watson, 2005). All histological procedures were
developed as previously reported (Murillo-Rodríguez et al., 2004;
Blanco-Centurión et al., 2006).
Statistical Analysis
As described in Experiment 2.
RESULTS
Effects on Sleep After Injections of
DZNep or GSK-J1 During the Lights-On
or the Lights-Off Period
In the first experiment, DZNep treatment (0.1, 1.0, or 10 mg/kg,
i.p.) given at the beginning of the lights-on period caused a
dose-dependent increase of W (Figure 1A; P < 0.0001) as well
as a decrease in SWS (Figure 1B; P < 0.0001) and REMS
(Figure 1C; P< 0.0001). Post hoc analysis test showed significant
differences between experimental groups for W, SWS, and REMS
(P < 0.0001). No statistical changes were observed in total W
(Figure 1D; P > 0.9), SWS (Figure 1E; P > 0.6), or REMS
(Figure 1F; P > 0.5) if drug was administered at the beginning
of the lights-off period. From data obtained, we conclude that
waking was enhanced by inhibiting methylase using DZNep if
administered during the lights-on period.
When GSK-J1 was injected (0.1, 1.0, or 10 mg/kg, i.p.)
at the beginning of the lights-on period, no statistical effects
were observed in total time of W (Figure 2A; P > 0.3),
SWS (Figure 2B; P > 0.6), or REMS (Figure 2C; P > 0.4).
However, if administered at the beginning of the lights-off
period, the inhibitor of histone demethylase decreased alertness
(Figure 2D; P< 0.0001), enhanced SWS (Figure 2E; P< 0.0001)
and decreased REMS (Figure 2F; P < 0.0003). Further
post hoc analysis test demonstrated significant differences
between experimental trials in W, SWS, and REMS (P < 0.0001).
We conclude that inhibition of histone demethylase promoted
sleep-inducing effect when injected during the lights-off period.
Effects on Sleep Parameters After
Administrations of DZNep or GSK-K1
During the Lights-On or the Lights-Off
Period
The sleep parameters (Table 1), including the frequency (number
of bouts), mean duration (min) and latency (min) of W,
SWS, and REMS were analyzed after pharmacological trials
following previous procedures (Murillo-Rodríguez et al., 2017).
In this regard, administration of DZNep during the lights-on
period induced no changes in the number of bouts of waking
(P > 0.1) whereas SWS (P < 0.002) and REMS were decreased
(P < 0.003). Scheffé’s post hoc test showed significant differences
between experimental groups for SWS and REMS (P < 0.01). In
addition, mean duration displayed statistical enhancements in W
(P < 0.04), with no changes in SWS (P > 0.3) but REMS was
found increased (P < 0.0001). The Scheffé’s post hoc test showed
us inter-group differences in W and REMS (P < 0.01). Lastly,
latency for SWS (P > 0.3) and REMS (P > 0.3) displayed no
statistical changes in rats that received DZNep.
The analysis of sleep parameters (Table 2) after injection
of DZNep during the lights-off period showed no statistical
differences among experimental trials in frequency of waking
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FIGURE 1 | Effects on total time (4 h of sleep recordings) of wakefulness (W), slow wave sleep (SWS), and rapid eye movement sleep (REMS) after injection of
vehicle (CTL [n = 5]) or DZNep (0.1, 1.0, or 10 mg/kg, i.p.; each dose, n = 5) during either lights-on or lights-off period. Effects were observed in W, SWS, or REMS
when DZNEp was injected during the lights-on period (A–C, respectively; ∗ vs. Control; # vs. DZNep-0.1, % vs. DZNep-1.0; P < 0.05). However, when administered
at the lights-off period, no changes in sleep stages were found (D–F, respectively).
(P > 0.5), SWS (P > 0.3) and REMS (P > 0.2). Mean duration
for W, SWS, and REMS showed no significant changes as well
(P > 0.6, P > 0.5, and P > 0.9, respectively). Alike results were
observed in latency for SWS (P> 0.4) and REMS (P> 0.4).
GSK-J1 caused no statistical differences (Table 3) once
injected during the lights-on period in the frequency of waking
(P> 0.7) but decreased the number of bouts in SWS (P< 0.0001)
and REMS (P < 0.05). The Scheffé’s post hoc test showed
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FIGURE 2 | Effects on total time (4 h of sleep recordings) of wakefulness, SWS, and REMS after injection of vehicle (CTL [n = 5]) or GSK-J1 (0.1, 1.0, or 10 mg/kg,
i.p.; each dose, n = 5) during either lights-on or lights-off period. When administered at the lights-on period, no effects in sleep stages were found
(A–C, respectively). However, if injected during the lights-off period, GSK-J1 decreased W, decreased SWS and diminished REMS (D–F, respectively; ∗ vs. Control; #
vs. GSK-0.1, % vs. GSK-1.0; P < 0.05).
inter-group differences in SWS and REMS (P < 0.005). Mean
duration showed no statistical differences in W (P > 0.1), SWS
(P > 0.1), or REMS (P > 0.7). Similar findings were observed in
latency for SWS (P > 0.1) and REMS (P> 0.2).
Table 4 shows the sleep parameters in GSK-J1-treated
rats across lights-off period. As demonstrated, no statistical
differences were found in frequency for W (P > 0.2) while a
significant decrease was observed in SWS (P < 0.03) as well
as REMS (P < 0.04). The Scheffé’s post hoc test displayed
differences for SWS (P < 0.008) and REMS (P < 0.05). Mean
duration showed no statistical changes in alertness (P > 0.5)
whereas a significant increase was found in SWS (P < 0.01)
and REMS (P < 0.005). The Scheffé’s post hoc test showed
differences for SWS (P < 0.009) and REMS (P < 0.01).
Finally, latency was found with no significant changes for
SWS (P > 0.1) but REMS displayed a significant diminution
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TABLE 1 | Effects on sleep parameters (frequency, mean duration, and latency) after the administration of vehicle (CTL [n = 5]) or DZNep (0.1, 1.0, or 10 mg/kg, i.p.;
each dose, n = 5) during lights-on period (∗ vs. Control; # vs. DZNep-0.1, % vs. DZNep-1.0; P < 0.05).
Wakefulness Frequency (number of bouts)
(F(3,16) = 1.849, P = 0.1)
Mean duration (min)
(F(3,16) = 3.484, P < 0.04)
Latency (min)
CTL 19.72 ± 1.0 1.70 ± 0.2 0.0 ± 0.0
DZNep-0.1 19.48 ± 1.1 1.80 ± 0.1 0.0 ± 0.0
DZNep-1.0 24.72 ± 3.6 3.44 ± 1.1 0.0 ± 0.0
DZNep-10 16.40 ± 3.1 4.69 ± 0.9∗,% 0.0 ± 0.0
Slow wave sleep Frequency (number of bouts)
(F(3,16) = 7.804, P < 0.002)
Mean duration (min)
(F(3,16) = 1.168, P = 0.3)
Latency (min)
(F(3,16) = 1.310, P = 0.3)
CTL 38.80 ± 1.9 2.96 ± 0.1 26.28 ± 4.0
DZNep-0.1 38.08 ± 1.4 3.01 ± 0.2 28.99 ± 4.0
DZNep-1.0 37.86 ± 3.8 4.48 ± 1.9 35.28 ± 3.7
DZNep-10 23.72 ± 3.0∗,#,% 5.32 ± 0.7 25.52 ± 4.2
REMS Frequency (number of bouts)
(F(3,16) = 7.092, P < 0.003)
Mean duration (min)
(F(3,16) = 13.946, P < 0.0001)
Latency (min)
(F(3,16) = 1.02, P = 0.3)
CTL 19.52 ± 2.3 0.80 ± 0.1 55.32 ± 12.8
DZNep-0.1 19.12 ± 2.3 0.80 ± 0.1 50.58 ± 12.8
DZNep-1.0 12.0 ± 1.3 1.04 ± 0.3 49.72 ± 7.8
DZNep-10 10.00 ± 0.8∗,% 2.50 ± 0.2∗,#,% 32.88 ± 4.0
TABLE 2 | Effects on sleep parameters (frequency, mean duration, and latency) after the injection of vehicle (CTL [n = 5]) or GSK-J1 (0.1, 1.0, or 10 mg/kg, i.p.; each
dose, n = 5) during lights-on period (∗ vs. Control; # vs. GSJ-0.1, % vs. GSK-1.0; P < 0.05).
Wakefulness Frequency (number of bouts)
(F(3,16) = 0.721, P = 0.5)
Mean duration (min)
(F(3,16) = 0.634, P = 0.6)
Latency (min)
CTL 17.70 ± 1.8 5.15 ± 2.9 0.0 ± 0.0
DZNep-0.1 23.43 ± 5.5 1.73 ± 0.2 0.0 ± 0.0
DZNep-1.0 17.70 ± 1.5 5.53 ± 2.7 0.0 ± 0.0
DZNep-10 19.20 ± 1.8 3.91 ± 1.3 0.0 ± 0.0
Slow wave sleep Frequency (number of bouts)
(F(3,16) = 1.186, P = 0.3)
Mean duration (min)
(F(3,16) = 0.675, P = 0.5)
Latency (min)
(F(3,16) = 0.865, P = 0.4)
CTL 35.50 ± 1.9 2.38 ± 0.2 28.40 ± 12.6
DZNep-0.1 26.53 ± 7.3 2.46 ± 0.3 28.14 ± 1.7
DZNep-1.0 32.20 ± 2.1 3.10 ± 0.5 41.28 ± 4.8
DZNep-10 35.60 ± 3.9 2.78 ± 0.3 39.52 ± 6.5
REMS Frequency (number of bouts)
(F(3,16) = 1.631, P = 0.2)
Mean duration (min)
(F(3,16) = 0.083, P = 0.9)
Latency (min)
(F(3,16) = 0.991, P = 0.4)
CTL 22.68 ± 1.5 0.88 ± 0.08 56.80 ± 12.9
DZNep-0.1 11.95 ± 4.0 0.83 ± 0.09 39.98 ± 4.5
DZNep-1.0 15.80 ± 2.9 0.80 ± 0.08 51.72 ± 3.7
DZNep-10 15.00 ± 4.7 0.80 ± 0.02 41.16 ± 2.1
(P < 0.01). Post hoc test showed significant changes for
REMS (P < 0.007).
Effects on Sleep Power Spectra After
Treatments of DZNep or GSK-J1 During
the Lights-On or the Lights-Off Period
Systemic injection of DZNep during lights-on enhanced alpha
(Figure 3A; P< 0.0001) as well as a decrease in delta (Figure 3B;
P < 0.0001) and theta power spectra (Figure 3C; P < 0.0001).
The Scheffé’s post hoc test showed inter-group differences for
alpha (P < 0.0001), delta (P < 0.0001), and theta power spectra
(P< 0.0001). No significant changes were found in power spectra
analysis for alpha (Figure 3D; P> 0.6), delta (Figure 3E; P> 0.6)
or theta (Figure 3F; P > 0.5) during the lights-off period in
DZNep-treated rats.
Next, we evaluated whether GSK-J1 would induce effects in
power spectra if injected during the lights-on or the lights-
off phase. Results showed that when administered at the
beginning of the lights-on period no statistical changes in
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TABLE 3 | Effects on sleep parameters (frequency, mean duration, and latency) after the treatment of vehicle (CTL [n = 5]) or DZNep (0.1, 1.0, or 10 mg/kg, i.p.; each
dose, n = 5) during lights-off period (∗ vs. Control; # vs. DZNep-0.1, % vs. DZNep-1.0; P < 0.05).
Wakefulness Frequency (number of bouts)
(F(3,16) = 0.405, P = 0.7)
Mean duration (min)
(F(3,16) = 2.152, P = 0.1)
Latency (min)
CTL 19.72 ± 1.0 1.70 ± 0.2 0.0 ± 0.0
GSK-0.1 21.62 ± 1.1 1.71 ± 0.3 0.0 ± 0.0
GSK-1.0 21.46 ± 3.7 3.62 ± 1.1 0.0 ± 0.0
GSK-10 23.14 ± 1.5 2.59 ± 0.1 0.0 ± 0.0
Slow wave sleep Frequency (number of bouts)
(F(3,16) = 23.793, P < 0.0001)
Mean duration (min)
(F(3,16) = 2.374, P = 0.1)
Latency (min)
(F(3,16) = 1.738, P = 0.1)
CTL 38.80 ± 1.9 2.96 ± 0.1 26.28 ± 4.0
GSK-0.1 37.86 ± 3.0 2.36 ± 0.2 21.60 ± 4.6
GSK-1.0 26.78 ± 3.5∗,# 7.60 ± 3.7 37.60 ± 9.9
GSK-10 13.44 ± 1.0∗,#,% 8.65 ± 1.8 18.08 ± 5.0
REMS Frequency (number of bouts)
(F(3,16) = 3.238, P < 0.05)
Mean duration (min)
(F(3,16) = 0.476, P = 0.7)
Latency (min)
(F(3,16) = 1.486, P = 0.2)
CTL 19.52 ± 2.3 0.80 ± 0.1 55.32 ± 12.8
GSK-0.1 20.80 ± 3.2 0.76 ± 0.04 36.92 ± 6.7
GSK-1.0 15.40 ± 2.9 0.75 ± 0.07 51.88 ± 13.9
GSK-10 10.20 ± 1.9∗,# 1.17 ± 0.5 27.56 ± 6.9
TABLE 4 | Effects on sleep parameters (frequency, mean duration, and latency) after the application of vehicle (CTL [n = 5]) or GSK-J1 (0.1, 1.0, or 10 mg/kg, i.p.; each
dose, n = 5) during lights-off period (∗ vs. Control; # vs. GSJ-0.1, % vs. GSK-1.0; P < 0.05).
Wakefulness Frequency (number of bouts)
(F(3,16) = 1.636, P = 0.2)
Mean duration (min)
(F(3,16) = 0.791, P = 0.5)
Latency (min)
CTL 17.70 ± 1.8 5.15 ± 2.9 0.0 ± 0.0
GSK-0.1 22.76 ± 3.0 5.05 ± 1.6 0.0 ± 0.0
GSK-1.0 27.70 ± 5.8 3.02 ± 1.3 0.0 ± 0.0
GSK-10 28.014 ± 3.2 1.81 ± 0.1 0.0 ± 0.0
Slow wave sleep Frequency (number of bouts)
(F(3,16) = 3.608, P < 0.03)
Mean duration (min)
(F(3,16) = 4.436, P < 0.01)
Latency (min)
(F(3,16) = 2.344, P = 0.1)
CTL 37.50 ± 1.9 2.38 ± 0.2 28.40 ± 12.3
GSK-0.1 34.22 ± 4.3 2.38 ± 0.2 45.04 ± 6.1
GSK-1.0 26.52 ± 7.7 12.72 ± 4.4∗,# 27.00 ± 8.4
GSK-10 17.74 ± 1.9∗,% 9.40 ± 2.2∗,% 13.88 ± 3.0%
REMS Frequency (number of bouts)
(F(3,16) = 6.583, P < 0.004)
Mean duration (min)
(F(3,16) = 6.153, P < 0.005)
Latency (min)
(F(3,16) = 4.515, P < 0.01)
CTL 22.68 ± 1.5 0.88 ± 0.08 56.80 ± 12.9
GSK-0.1 12.00 ± 2.8∗ 0.63 ± 0.1 56.96 ± 6.9
GSK-1.0 11.20 ± 1.8∗ 0.50 ± 0.08∗ 34.80 ± 8.9
GSK-10 12.60 ± 2.0∗ 1.05 ± 0.1#,% 18.60 ± 3.5∗,%
alpha (Figure 4A; P > 0.6), delta (Figure 4B; P > 0.6),
or theta power spectra (Figure 4C; P > 0.6) were observed.
Although if given at the beginning of the lights-off period, the
histone demethylation inhibitor diminished alpha (Figure 4D;
P < 0.0001), but increased SWS (Figure 4E; P < 0.0001)
and reduced theta power spectra (Figure 4F; P < 0.0001).
The Scheffé’s post hoc test showed inter-group differences for
alpha (P < 0.0001), delta (P < 0.0001), and theta power
spectra (P < 0.0001).
Effects on the Extracellular Levels of
Monoamines, Adenosine, and
Acetylcholine After Administrations of
DZNep or GSK-J1
The localization of the microdialysis probe in the AcbC or
basal forebrain is shown in Figure 5. The schematic illustration
of the position of the probe into ACbC (Figure 5A) or basal
forebrain (Figure 5B) is displayed whereas microphotographies
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FIGURE 3 | Effects on alpha (during W), delta (across SWS), and theta power spectra (during REMS) after injection of vehicle (CTL [n = 5]) or DZNep (0.1, 1.0, or
10 mg/kg, i.p.; each dose, n = 5) during either lights-on or lights-off period. Effects were observed in alpha, delta and theta power spectra when DZNEp was injected
during the lights-on period (A–C, respectively; ∗ vs. Control; # vs. DZNep-0.1, % vs. DZNep-1.0; P < 0.05). However, when administered at the lights-off period, no
changes in power spectra were found (D–F, respectively).
from localization of microdialysis cannuale track into ACbC and
basal forebrain is also shown (Figures 5C,D, respectively).
Since statistical changes in DZNep-treated rats were
observed in sleep studies during the lights-on period
(see section “Results”), our next aim was to determinate
whether administrations of this compound would promote
neurochemical changes if injected only at the beginning of
the lights-on period. Having this aim in mind, we injected
DZNep (0.1, 1.0, or 10 mg/kg, i.p.) to rats and collected
samples from microdialysis probes during the lights-on phase.
Injection of compound caused a dose-dependent enhancement
in extracellular contents of DA (Figure 6A; P < 0.0001), NE
(Figure 6B; P < 0.0001), EP (Figure 6C; P < 0.0001), 5-HT
(Figure 6D; P < 0.0001), AD (Figure 6E; P < 0.0001), and
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FIGURE 4 | Effects on alpha (during W), delta (across SWS), and theta power spectra (during REMS) after administration of vehicle (CTL [n = 5]) or GSK-J1 (0.1, 1.0,
or 10 mg/kg, i.p.; each dose, n = 5) during either lights-on or lights-off period. When administered at the lights-on period, GSK-J1 caused no statistical changes in
alpha, delta or theta power spectra (A–C, respectively). However, if injected during the lights-off period, GSK-J1 decreased alpha but decreased delta and
diminished theta power spectra (D–F, respectively; ∗ vs. Control; # vs. GSK-0.1, % vs. GSK-1.0; P < 0.05).
ACh (Figure 6F; P < 0.0001). The Scheffé’s post hoc test
showed inter-group significant differences for DA (P < 0.0001),
NE (P < 0.0001), EP (P < 0.0001), 5-HT (P < 0.0001), AD
(P < 0.0001), and ACh (P < 0.03). We conclude that DZNep
was able to increase several sleep-related neurochemicals when
injected during the lights-on period.
In the following experiment, we evaluated if GSK-J1 would be
able to provoke effects in extracellular levels of DA, NE, EP, 5-HT,
AD, and ACh. Due that GSK-J1 exerted influence on sleep during
the lights-off period, we administered this compound (0.1, 1.0, or
10 mg/kg, i.p.) at the beginning of the dark period. A decrease
in a dose-dependent fashion of the contents of DA (Figure 7A;
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FIGURE 5 | Localization of the microdialysis probe in the microdialysis experiments. (A,B) Shows the schematic illustration from the rat brain atlas (Paxinos and
Watson, 2005) with the location of the microdialysis probe in AcbC (coordinates: A = +1.2, L = +2.0, and H = –7.0 mm, with reference to Bregma [Paxinos and
Watson, 2005]) or basal forebrain (coordinates: A = –0.35; L = 2.0; and H = –7.5 mm, with reference to Bregma [Paxinos and Watson, 2005]), respectively.
Microphotographies show the microdialysis probe track in AcbC or basal forebral in (C,D), respectively. Abbreviations were taken from the Paxinos and Watson
(2005): AcbC, nucleus accumbens; LPO, lateral preoptic area. Scale bar: 100 µm.
P < 0.0001), NE (Figure 7B; P < 0.0001), EP (Figure 7C;
P < 0.0001), 5-HT (Figure 7D; P < 0.0001), AD (Figure 7E;
P < 0.0001), and ACh (Figure 7F; P < 0.0001) was found. The
Scheffé’s post hoc test showed inter-group significant differences
for DA (P < 0.0001), NE (P < 0.0001), EP (P < 0.0001), 5-HT
(P < 0.0001), AD (P < 0.0004), and ACh (P < 0.0001). In
conclusion, GSK-J1 diminished the levels of neurochemicals if
administered during the lights-off period.
DISCUSSION
Histone methylation/demethylation activity has been studied in
several biomedical aspects, with emphasis in cancer (Kunts et al.,
2017; Pérez et al., 2018; Porcellini et al., 2018; Tong et al.,
2018; Wijenayake et al., 2018). Despite significant advances have
been achieved by studying the molecular role of histones in
regulating health conditions, no direct evidence was available
regarding the influence of histone methylation/demethylation
activity on neurobiological phenomena such as the sleep-wake
cycle and sleep-related neurochemicals. Here, we described
that histone methylation inhibition by DZNep enhanced
waking if injected during the lights-on period whereas histone
demethylation inhibition by GSK-J1 caused a sleep-inducing
effect if administered during the lights-off period. Further effects
were observed in DZNep-treated rats in sleep parameters during
the lights-on period. In addition, animals that received GSK-J1
showed changes in sleep parameters only if injected during
the lights-off period. Moreover, animals that received DZNep
showed across the lights-on period an increase in alpha power
spectra whereas delta and theta were found increased, in SWS
and REMS, respectively. Opposite findings were observed in
GSK-J1-treated animals during the lights-off since they displayed
a significant enhancement in alpha power spectra as well as
a decrease in delta and theta power spectra, during SWS and
REMS, respectively. In addition, the histone methylation activity
also induced neurochemical changes. For instance, DZNep
injection at the beginning of the lights-on period caused a
dose-dependent enhancement in extracellular contents of DA,
NE, EP, 5-HT, AD, and ACh whereas GSK-J1 administered
at the beginning of the lights-off period, decreased the levels
of the neurochemicals mentioned above. We conclude that
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FIGURE 6 | Effects on extracellular levels of dopamine, norepinephrine, epinephrine, 5-HT, adenosine, and acetylcholine (4 h of sampling) after the injection of
vehicle (CTL [n = 5]) or DZNep (0.1, 1.0, or 10 mg/kg, i.p.; each dose, n = 5) during the lights-on period. Effects were observed as an increase in contents of
dopamine, norepinephrine, epinephrine, 5-HT, adenosine and acetylcholine after pharmacological challenge (A–F, respectively; ∗ vs. Control; # vs. DZNep-0.1, % vs.
DZNep-1.0; P < 0.05).
effects observed after the administration of the drugs during
the light or dark phase suggest a possible sensitivity of the
availability of histone methylation or demethylation depending
on the phase of the light–dark cycle. This possible sensitivity
could be the cause of the effects observed in sleep and
neurochemical levels.
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FIGURE 7 | Effects on extracellular levels of dopamine, norepinephrine, epinephrine, 5-HT, adenosine, and acetylcholine (4 h of sampling) after the administration of
vehicle (CTL [n = 5]) or GSK-J1 (0.1, 1.0, or 10 mg/kg, i.p.; each dose, n = 5) during the lights-off period. The levels of dopamine, norepinephrine, epinephrine, 5-HT,
adenosine, and acetylcholine were found decreased after pharmacological trials (A–F, respectively; ∗ vs. Control; # vs. GSK-0.1, % vs. GSK-1.0; P < 0.05).
Although current findings provide novel insights of the likely
role of inhibition of either histone methylation or histone
demethylation on sleep and neurochemicals modulation, several
limitations in the current study have been identified. For
example, it is difficult to determine whether the changes observed
in sleep may be cause or effect on the variations found in
the neurochemicals analyzed. Moreover, previous reports have
indicated that DZNep globally inhibits histone methylation
acting as a non-selective molecular drug (Miranda et al., 2009).
Thus, experiments testing the effects on sleep by using selective
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drugs should be design in the near future. Furthermore, the
compounds were administered by systemic route raising the
possibility that central injections (i.c.v. or into parenchyma)
might provoke different results. Future studies using histone
methylation/demethylation inhibitors may target brain areas
related to the control of the sleep-wake cycle such as thalamus,
hypothalamus or pedunculopontine tegmentum nucleus.
Novel therapies aimed to treat cancer by using histone
methylation drugs show positive results (Harb-de la Rosa et al.,
2015; Pleyer and Greil, 2015; Castilho et al., 2017; Choi et al.,
2017; Curry et al., 2018). It would be interesting to determine
whether using DZNep may control sleepiness in patients with
cancer or if GSK-J1 might modulate insomnia caused by stress
prior to undergoing radiotherapy (Davies et al., 2017; Vin-Raviv
et al., 2017; Miladinia et al., 2018; Zhou et al., 2018). Testing
this hypothesis in experimental models of sleep disturbances
would give us an important comprehensive insight of the
role of histone methylation/demethylation in the management
of sleep disturbances. Moreover, circadian fluctuations of
histone methylation/demethylation activity would provide us
foundations for in which ‘time’ becomes a critical variable to
obtain the desirable effects. Thus, chronopharmacological studies
would embrace endogenous periodicities and biological timing
of the activity of histones to ensure that drugs are acting on
time coupled with these rhythmicities and, then enhance the
expected effects.
Although limited evidence is available in regards the role of
histone methylation/demethylation activity in neurobiological
phenomena, our studies extend these data to suggest that
nuclear elements could induce sleep and neurochemical
modulation (Duan et al., 2016; Gaine et al., 2018; Morales-
Lara et al., 2018; Shalaby et al., 2018). Following this idea,
we have developed a conceptual framework that suggests that
manipulation of histone methylation/demethylation activity
could engage sleep-related genes: chromatin organization by
histone methylation/demethylation, implies the modulation of
the activity of large numbers of genes (MacPherson et al., 2018;
Lamadema et al., 2019; Ricketts et al., 2019), including those
that have been associated with sleep control (Wang and Liu,
2016; Tomita et al., 2017; Kim et al., 2018). However, the role
of histone methylation/demethylation in sleep remains poorly
understood. Therefore, this is the first direct evidence that
drugs aimed to inhibits histone methylation or demethylation
are related with sleep and neurochemicals effects. In addition,
the importance of DNA-methylation and demethylation in
neurotransmission has been partially studied. Despite that
several studies have reported the link between methylation or
demethylation effects on several neurobiological processes, such
as learning and memory as well as pathological conditions, it
is difficult to draw solid conclusions about how the histone
methylation and demethylation inhibition may exert influence
on the neurotransmitter contents. The available data regarding
the modifications of histones in conjunction with behavior,
implicitly suggest changes in neurotransmission (Sun et al., 2013;
Cholewa-Waclaw et al., 2016; Bayraktar and Kreutz, 2018). With
respect to those results seen with relationship between behavioral
functions and histone activity, it is conceivable that perhaps those
effects could be attributable to neurotransmitters alterations.
However, it remains to be described if histone methylation and
demethylation inhibition induce changes in neurotransmitters
by engaging enzymatic process involved in the formation of
DA, NE, EP, 5-HT, AD, and ACh. It cannot be rule out that
enzymatic component in the metabolic pathway of studied
neurotransmitters could be inhibited by the methylation or
demethylation inhibition. Importantly, the DNA methylation
and histone acetylation have been implicated in the modulation
of synaptic transmission of several neurotransmitters, including
key genes in the GABAergic pathway (Nelson and Monteggia,
2011; Holloway and González-Maeso, 2015; Shrestha and Offer,
2016). Indeed, complementary experiments testing the role of
methylation and demethylation inhibition on the biosynthesis
of DA, NE, EP, 5-HT, AD, and ACh are needed to provide
better understanding of the phenomena. Further studies will
be required to determine the specific mechanism of action of
DZNep or GSK-J1 on sleep and neurochemical modulation.
We assume that in the near future, additional studies might
describe the histone methylation or demethylation profiles as
molecular markers for diagnostics of sleep disturbances or the
application of drugs such as DZNep or GSK-J1 at specific time
of the circadian rhythm as therapeutic strategy. Taken together,
our findings demonstrate that histone methylation inhibition
promotes waking whereas sleep is promoted when histone
demethylation is suppressed.
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